{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:09:49Z","timestamp":1781082589040,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40272-018-0298-9","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T21:58:26Z","timestamp":1527717506000},"page":"293-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia"],"prefix":"10.1007","volume":"20","author":[{"given":"Ruairi","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5246","authenticated-orcid":false,"given":"Christina","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"issue":"3","key":"298_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","volume":"9","author":"CH Pui","year":"2008","unstructured":"Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257\u201368.","journal-title":"Lancet Oncol."},{"issue":"3","key":"298_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199\u2013209.","journal-title":"Lancet Oncol."},{"issue":"2","key":"298_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1200\/JCO.2003.04.096","volume":"21","author":"B Burger","year":"2003","unstructured":"Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21(2):184\u20138.","journal-title":"J Clin Oncol."},{"issue":"60","key":"298_CR4","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"CH Pui","year":"2009","unstructured":"Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(60):2730\u201341.","journal-title":"N Engl J Med."},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-8722-4-42","volume":"4","author":"C Halsey","year":"2011","unstructured":"Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4:42.","journal-title":"J Hematol Oncol."},{"issue":"10","key":"298_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","volume":"10","author":"AJ Veerman","year":"2009","unstructured":"Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997\u20132004). Lancet Oncol. 2009;10(10):957\u201366.","journal-title":"Lancet Oncol."},{"issue":"9","key":"298_CR7","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","volume":"104","author":"CH Pui","year":"2004","unstructured":"Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children\u2019s Research Hospital. Blood. 2004;104(9):2690\u20136.","journal-title":"Blood."},{"issue":"9","key":"298_CR8","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","volume":"111","author":"A M\u00f6ricke","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477\u201389.","journal-title":"Blood."},{"issue":"3","key":"298_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896\u2013904.","journal-title":"Blood."},{"issue":"7315","key":"298_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(63)90681-0","volume":"2","author":"AK Ommaya","year":"1963","unstructured":"Ommaya AK. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963;2(7315):983\u20134.","journal-title":"Lancet."},{"key":"298_CR11","volume-title":"The medulloblastoma book","author":"L Meijer","year":"2014","unstructured":"Meijer L, Walker D, Slavc I. Intra-cerebrospinal fluid therapy for leptomeningeal metastases in medulloblastoma. In: Kombogiorgas DA, editor. The medulloblastoma book. Hauppauge: Nova Science Publishers, Inc.; 2014."},{"issue":"1","key":"298_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11060-014-1531-1","volume":"120","author":"A Peyrl","year":"2014","unstructured":"Peyrl A, Chocholous M, Azizi AA, Czech T, Dorfer C, Mitteregger D, Gojo J, Minichmayr E, Slavc I. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. J Neurooncol. 2014;120(1):139\u201345.","journal-title":"J Neurooncol."},{"issue":"3","key":"298_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jinf.2013.11.014","volume":"68","author":"PA Mead","year":"2014","unstructured":"Mead PA, Safdieh JE, Nizza P, Tuma S, Sepkowitz KA. Ommaya reservoir infections: a 16-year retrospective analysis. J Infect. 2014;68(3):225\u201330.","journal-title":"J Infect."},{"issue":"3","key":"298_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1445-5994.1986.tb01190.x","volume":"16","author":"GA Young","year":"1986","unstructured":"Young GA, Milliken S, Jurd J, Poulgrain P, Vincent PC. The intraventricular reservoir in the treatment of neurological disease secondary to hematological malignancy: an eight year experience. Aust NZ J Med. 1986;16(3):373\u20137.","journal-title":"Aust NZ J Med."},{"issue":"1","key":"298_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/archinte.1990.00390130145023","volume":"150","author":"M Lishner","year":"1990","unstructured":"Lishner M, Perrin RG, Feld R, Messner HA, Tuffnell PG, Elhakim T, Matlow A, Curtis JE. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med. 1990;150(1):173\u20136.","journal-title":"Arch Intern Med."},{"issue":"2","key":"298_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00006454-198702000-00008","volume":"6","author":"MJ Browne","year":"1987","unstructured":"Browne MJ, Dinndorf PA, Perek D, Commers J, Bleyer WA, Poplack DG, Pizzo PA. Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J. 1987;6(2):182\u20139.","journal-title":"Pediatr Infect Dis J."},{"issue":"6","key":"298_CR17","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/1097-0142(197806)41:6<2431::AID-CNCR2820410650>3.0.CO;2-3","volume":"41","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA, Pizzo PA, Spence AM, Platt WD, Benjamin DR, Kolins CJ, Poplack DG. The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer. 1978;41(6):2431\u20137.","journal-title":"Cancer."},{"key":"298_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/archneur.1981.00510070084016","volume":"38","author":"RJ Packer","year":"1981","unstructured":"Packer RJ, Zimmerman RA, Rosenstock J, et al. Focal encephalopathy following methotrexate therapy: administration via a misplaced intraventricular catheter. Arch Neurol. 1981;38:450\u20132.","journal-title":"Arch Neurol."},{"key":"298_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01850981","volume":"6","author":"V Colamaria","year":"1990","unstructured":"Colamaria V, Carabello R, Borgna-Pignatti C, et al. Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine; a complication of Ommaya reservoir: case report and review of the literature. Child\u2019s Nerv Syst. 1990;6:231\u20135.","journal-title":"Child\u2019s Nerv Syst."},{"issue":"6","key":"298_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000442423","volume":"93","author":"BC Kennedy","year":"2015","unstructured":"Kennedy BC, Brown LT, Komotar RJ, McKhann GM 2nd. Frameless stereotactic ommaya reservoir placement: efficacy and complication comparison with frame-based technique. Stereotact Funct Neurosurg. 2015;93(6):415\u20138.","journal-title":"Stereotact Funct Neurosurg."},{"key":"298_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clineuro.2014.12.018","volume":"130","author":"GM Weiner","year":"2015","unstructured":"Weiner GM, Chivukula S, Chen CJ, Ding D, Engh JA, Amankulor N. Ommaya reservoir with ventricular catheter placement for chemotherapy with frameless and pinless electromagnetic surgical neuronavigation. Clin Neurol Neurosurg. 2015;130:61\u20136.","journal-title":"Clin Neurol Neurosurg."},{"key":"298_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.wneu.2016.04.090","volume":"93","author":"PF Morgenstern","year":"2016","unstructured":"Morgenstern PF, Connors S, Reiner AS, Greenfield JP. Image guidance for placement of ommaya reservoirs: comparison of fluoroscopy and frameless stereotactic navigation in 145 patients. World Neurosurg. 2016;93:154\u20138.","journal-title":"World Neurosurg."},{"key":"298_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/annonc\/mdm466","volume":"19","author":"H Inaba","year":"2008","unstructured":"Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008;19:178\u201384.","journal-title":"Ann Oncol."},{"issue":"9","key":"298_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","volume":"32","author":"D Bhojwani","year":"2014","unstructured":"Bhojwani D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949\u201359.","journal-title":"J Clin Oncol."},{"issue":"4","key":"298_CR25","first-page":"1765","volume":"27","author":"J Bond","year":"2013","unstructured":"Bond J, Hough R, Moppett J, Vora A, Mitchell C, Goulden N. \u2018Stroke-like syndrome\u2019 caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial. Leukaemia. 2013;27(4):1765\u20139.","journal-title":"Leukaemia."},{"issue":"10","key":"298_CR26","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(16)30110-7","volume":"3","author":"YT Cheung","year":"2016","unstructured":"Cheung YT, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Hematol. 2016;3(10):e456\u201366.","journal-title":"Lancet Hematol."},{"issue":"6","key":"298_CR27","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","volume":"17","author":"K Schmiegelow","year":"2016","unstructured":"Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231\u20139.","journal-title":"Lancet Oncol."},{"issue":"22","key":"298_CR28","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1200\/JCO.2015.65.4574","volume":"34","author":"KR Krull","year":"2016","unstructured":"Krull KR, et al. Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2016;34(22):2644\u201353.","journal-title":"J Clin Oncol."},{"issue":"11","key":"298_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2015.64.3205","volume":"34","author":"LM Jacola","year":"2016","unstructured":"Jacola LM, et al. Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol. J Clin Oncol. 2016;34(11):1239\u201347.","journal-title":"J Clin Oncol."},{"issue":"35","key":"298_CR30","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2012.48.2315","volume":"31","author":"KR Krull","year":"2013","unstructured":"Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, Gurney JG, Kimberg C, Krasin MJ, Pui CH, Robinson LL, Hudson MM. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukaemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407\u201315.","journal-title":"J Clin Oncol."},{"issue":"1","key":"298_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/pbc.25690","volume":"63","author":"A Kanellopoulos","year":"2016","unstructured":"Kanellopoulos A, et al. Neurocognitive outcome in very long-term survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only. Pediatr Blood Cancer. 2016;63(1):133\u20138.","journal-title":"Pediatr Blood Cancer."},{"issue":"5","key":"298_CR32","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1200\/JCO.1998.16.5.1712","volume":"16","author":"DH Mahoney Jr","year":"1998","unstructured":"Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy\u2014a Pediatric Oncology Group study. J Clin Oncol. 1998;16(5):1712\u201322.","journal-title":"J Clin Oncol."},{"issue":"5","key":"298_CR33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00280-016-3153-0","volume":"78","author":"VJ Forster","year":"2016","unstructured":"Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol. 2016;78(5):1093\u20136.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"298_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0014-2964(72)90125-9","volume":"8","author":"JH Goldie","year":"1972","unstructured":"Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer. 1972;8(4):409\u201314.","journal-title":"Eur J Cancer."},{"issue":"4","key":"298_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM197507242930402","volume":"293","author":"WR Shapiro","year":"1975","unstructured":"Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161\u20136.","journal-title":"N Engl J Med."},{"issue":"5","key":"298_CR36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V51.5.835.835","volume":"51","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA, Poplack DG, Simon RM. \u201cConcentration\u00a0\u00d7\u00a0time\u201d methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978;51(5):835\u201342.","journal-title":"Blood."},{"issue":"2","key":"298_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/00043426-200302000-00006","volume":"25","author":"BC Bostrom","year":"2003","unstructured":"Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol. 2003;25(2):114\u20137.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"5","key":"298_CR38","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.1997.15.5.1824","volume":"15","author":"A Thyss","year":"1997","unstructured":"Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children\u2019s Leukemia Cooperative Group. J Clin Oncol. 1997;15(5):1824\u201330.","journal-title":"J Clin Oncol."},{"key":"298_CR39","first-page":"435","volume":"43","author":"BM Mehta","year":"1983","unstructured":"Mehta BM, Glass JP, Shapiro WR. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res. 1983;43:435\u20138.","journal-title":"Cancer Res."},{"issue":"7","key":"298_CR40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/archdischild-2014-307036","volume":"100","author":"LJ Ells","year":"2015","unstructured":"Ells LJ, Hancock C, Copley VR, et al. Prevalence of severe childhood obesity in England: 2006\u20132013. Arch Dis Child. 2015;100(7):631\u20136.","journal-title":"Arch Dis Child."},{"issue":"14","key":"298_CR41","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/CIRCULATIONAHA.111.047738","volume":"126","author":"R Lakshman","year":"2012","unstructured":"Lakshman R, Elks CE, Ong KK. Childhood obesity. Circulation. 2012;126(14):1770\u20139.","journal-title":"Circulation."},{"issue":"9","key":"298_CR42","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1200\/JCO.1985.3.9.1217","volume":"3","author":"P Steinherz","year":"1985","unstructured":"Steinherz P, Jereb B, Galicich J. Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy. J Clin Oncol. 1985;3(9):1217\u201326.","journal-title":"J Clin Oncol."},{"key":"298_CR43","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/mpo.2950060304","volume":"6","author":"WA Bleyer","year":"1979","unstructured":"Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous system leukaemia: prolonged remission with the ommaya reservoir. Med Pediatr Oncol. 1979;6:2017\u2013213.","journal-title":"Med Pediatr Oncol."},{"key":"298_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/oxfordjournals.annonc.a059187","volume":"6","author":"M Iacoangeli","year":"1995","unstructured":"Iacoangeli M, Roselli R, Pagano L, et al. Intrathecal chemotherapy for treatment of overt meningeal leukaemia: comparison between intraventricular and traditional intralumbar route. Ann Oncol. 1995;6:377\u201382.","journal-title":"Ann Oncol."},{"issue":"1","key":"298_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","volume":"41","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36\u201351.","journal-title":"Cancer."},{"issue":"11","key":"298_CR46","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1172\/JCI106181","volume":"48","author":"WM Hryniuk","year":"1969","unstructured":"Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical\u2013biochemical correlates. J Clin Invest. 1969;48(11):2140\u201355.","journal-title":"J Clin Invest."},{"issue":"9","key":"298_CR47","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/1097-0142(19821101)50:9<1676::AID-CNCR2820500903>3.0.CO;2-S","volume":"50","author":"LJ Ettinger","year":"1982","unstructured":"Ettinger LJ, Chervinsky DS, Freeman AI, Creaven PJ. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin\u2019s lymphoma. Cancer. 1982;50(9):1676\u201382.","journal-title":"Cancer."},{"key":"298_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1056\/NEJM197508212930807","volume":"293","author":"AM Mauer","year":"1975","unstructured":"Mauer AM. Cell Kinetics and practical consequences for therapy of acute leukaemia. N Engl J Med. 1975;293:389\u201393.","journal-title":"N Engl J Med."},{"issue":"11","key":"298_CR49","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.1989.7.11.1741","volume":"7","author":"DR Strother","year":"1989","unstructured":"Strother DR, Glynn-Barnhart A, Kovnar E, Gregory RE, Murphy SB. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J Clin Oncol. 1989;7(11):1741\u20137.","journal-title":"J Clin Oncol."},{"key":"298_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1097-0142(197507)36:1<232::AID-CNCR2820360126>3.0.CO;2-F","volume":"36","author":"AH-M Kuo","year":"1975","unstructured":"Kuo AH-M, Xenophon Y, Galicich H, Fried J, Clarkson BD. Proliferative kinetics of central nervous system (CNS) leukaemia. Cancer. 1975;36:232\u20139.","journal-title":"Cancer."},{"key":"298_CR51","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/1097-0142(197809)42:3<1255::AID-CNCR2820420334>3.0.CO;2-M","volume":"42","author":"J Tsuchiya","year":"1978","unstructured":"Tsuchiya J, Moteki M, Shimano S, Shinonome S, Suda T, Omine M, Maekawa T. Proliferative kinetics of the leukaemic cells in meningeal leukaemia. Cancer. 1978;42:1255\u201362.","journal-title":"Cancer."},{"key":"298_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2045-8118-11-10","volume":"11","author":"T Brinker","year":"2014","unstructured":"Brinker T, Stopa E, Morrison J, Klinge P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11:10.","journal-title":"Fluids Barriers CNS."},{"issue":"15","key":"298_CR53","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1056\/NEJM197310112891503","volume":"289","author":"WA Bleyer","year":"1973","unstructured":"Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973;289(15):770\u20133.","journal-title":"N Engl J Med."},{"issue":"1","key":"298_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.1985.3.1.19","volume":"3","author":"M Morse","year":"1985","unstructured":"Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack D, Bleyer A. Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse. J Clin Oncol. 1985;3(1):19\u201324.","journal-title":"J Clin Oncol."},{"issue":"5","key":"298_CR55","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/0002-9343(82)90404-1","volume":"73","author":"SA Grossman","year":"1982","unstructured":"Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med. 1982;73(5):641\u20137.","journal-title":"Am J Med."},{"issue":"1","key":"298_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.26.1.1","volume":"26","author":"GD Chiro","year":"1976","unstructured":"Chiro GD, Hammock MK, Bleyer WA. Spinal descent of cerebrospinal fluid in man. Neurology. 1976;26(1):1\u20138.","journal-title":"Neurology."},{"key":"298_CR57","first-page":"555","volume":"12","author":"S Larson","year":"1971","unstructured":"Larson S, Schall G, Di Chrio G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med. 1971;12:555\u20137.","journal-title":"J Nucl Med."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-018-0298-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T17:41:32Z","timestamp":1571420492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-018-0298-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1007\/s40272-018-0298-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"31 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"There was no external funding for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ruairi Wilson, Caroline Osborne, and Christina Halsey declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}